Modeling disease progression in acute stroke using clinical assessment scales

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 683-691

  Karlsson, Kristin E ^a   Wilkins, Justin J ^a   Jonsson, Fredrik ^b   Zingmark, Per Henrik ^c   Karlsson, Mats O ^a   Jonsson, E Niclas ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b CERTARA   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d Exprimo NV   (Belgium)

Author keywords

Barthel index; Disease progression; NIH stroke scale; NONMEM; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; BARTHEL INDEX; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTION; PROGNOSIS; SIMULATION; STATISTICAL MODEL; STROKE;

ACUTE DISEASE; DISEASE PROGRESSION; HUMANS; MODELS, THEORETICAL; STROKE;

EID: 78649664750     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9230-0     Document Type: Article

References (41)

1. Mackay J, Mensah G. Atlas of heart disease and stroke. Switzerland: Geneva; 2004.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group 1995 Tissue plasminogen activator for acute ischemic stroke New England Journal of Medicine 333 24 1581 1587 10.1056/NEJM199512143332401
3. The RANTTAS Investigators 1996 A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS) Stroke 27 9 1453 1458
4. SM Davis GW Albers HC Diener KR Lees J Norris 1997 Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committee Lancet 349 9044 32 1:STN:280:DyaK2s7kvVGhtw%3D%3D 10.1016/S0140-6736(05)62166-6 8999265 (Pubitemid 27022998)
5. PP De Deyn JD Reuck W Deberdt R Vlietinck JM Orgogozo 1997 Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group Stroke 28 12 2347 2352 9412612
6. HC Diener 1998 Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group Cerebrovascular Disease 8 3 172 181 1:STN:280:DyaK1c3otFSjsg%3D%3D 10.1159/000015847 (Pubitemid 28192819)
7. EC Haley Jr 1998 High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators Stroke 29 6 1256 1257 9626304
8. W Hacke M Kaste C Fieschi R von Kummer A Davalos D Meier V Larrue E Bluhmki S Davis G Donnan D Schneider E Diez-Tejedor P Trouillas 1998 Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators Lancet 352 9136 1245 1251 1:CAS:528: DyaK1cXnt1egtLo%3D 10.1016/S0140-6736(98)08020-9 9788453 (Pubitemid 28470336)
9. WM Clark S Wissman GW Albers JH Jhamandas KP Madden S Hamilton 1999 Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3-5 h after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Journal of the American Medical Assocation 282 21 2019 2026 1:CAS:528: DC%2BD3cXhtFer 10.1001/jama.282.21.2019
10. KR Lees K Asplund A Carolei SM Davis HC Diener M Kaste JM Orgogozo J Whitehead 2000 Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators Lancet 355 9219 1949 1954 1:CAS:528: DC%2BD3cXks1Srsbg%3D 10.1016/S0140-6736(00)02326-6 10859040
11. RL Sacco JT DeRosa EC Haley Jr B Levin P Ordronneau SJ Phillips T Rundek RG Snipes JL Thompson 2001 Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial Journal of the American Medical Assocation 285 13 1719 1728 1:CAS:528:DC%2BD3MXivFGnu74%3D 10.1001/jama.285.13.1719
12. EAST Investigators 2001 Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial Neurology 57 8 1428 1434
13. GW Albers LB Goldstein D Hall LM Lesko 2001 Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial Journal of the American Medical Association 286 21 2673 2682 1:CAS:528:DC%2BD3MXovFSks78%3D 10.1001/jama.286.21.2673 11730442
14. M Krams KR Lees W Hacke AP Grieve JM Orgogozo GA Ford 2003 Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke Stroke 34 11 2543 2548 1:CAS:528: DC%2BD3sXosFCgtro%3D 10.1161/01.STR.0000092527.33910.89 14563972 (Pubitemid 37392736)
15. KW Muir KR Lees I Ford S Davis 2004 Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial Lancet 363 9407 439 445 1:STN:280:DC%2BD2c%2FnsVWgsA%3D%3D 10.1016/S0140- 6736(04)15490-1 14962524 (Pubitemid 38210060)
16. G Ladurner P Kalvach H Moessler 2005 Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial Journal of Neural Transmission 112 415 28 1:CAS:528:DC%2BD2MXhsVOmtrg%3D 10.1007/s00702-004-0248-2 15583955 (Pubitemid 40868052)
17. GJ Del Zoppo 1995 Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow Journal of Internal Medicine 237 1 79 88 10.1111/j.1365-2796.1995.tb01144.x 7830035
18. J Grotta 1995 Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy Journal of Internal Medicine 237 1 89 94 1:STN:280:DyaK2M7jtFWlsA%3D%3D 10.1111/j.1365-2796.1995.tb01145.x 7830036
19. KW Muir DG Grosset 1999 Neuroprotection for acute stroke: making clinical trials work Stroke 30 1 180 182 1:STN:280:DyaK1M%2FpslWitg%3D%3D 9880407
20. AR Green 2002 Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective Clinical and Experimental Pharmacology and Physiology 29 11 1030 1034 1:CAS:528:DC%2BD38XnslSksL4%3D 10.1046/j.1440-1681.2002.03767.x 12366397 (Pubitemid 35177173)
21. J Grotta 2002 Neuroprotection is unlikely to be effective in humans using current trial designs Stroke 33 1 306 307 11779929
22. GP Samsa DB Matchar 2001 Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles Stroke 32 3 669 674 1:STN:280:DC%2BD3M3islCisA%3D%3D 11239185
23. CS Weaver J Leonardi-Bee FJ Bath-Hextall PM Bath 2004 Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome Stroke 35 5 1216 1224 10.1161/01.STR.0000125010.70652.93 15031455 (Pubitemid 38543546)
24. Project management in the pharmaceutical industry: a survey of perceived success factors 1995-1996. Pharmaceutical Education & Research Institute: 1997.
25. Food and Drug Administration. Guidance for Industry: E9 Statistical Principles for Clinical Trials. Food and Drug Administration: Rockville, Maryland, USA, 1998.
26. JM Oxbury RC Greenhall KM Grainger 1975 Predicting the outcome of stroke: acute stage after cerebral infarction British Medical Journal 3 5976 125 1:STN:280:DyaE2M7osVyqsA%3D%3D 10.1136/bmj.3.5976.125 1139257
27. F Jonsson S Marshall M Krams EN Jonsson 2005 A longitudinal model for non-monotonic clinical assessment scale data Journal of Pharmacokinetics and Pharmacodynamics 32 5-6 795 815 10.1007/s10928-005-0098-z 16284913 (Pubitemid 41772358)
28. P Lyden T Brott B Tilley KM Welch EJ Mascha S Levine EC Haley J Grotta J Marler 1994 Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group Stroke 25 11 2220 2226 1:STN:280: DyaK2M%2FmsVyksw%3D%3D 7974549
29. FI Mahoney DW Barthel 1965 Functional evaluation: the Barthel Index Maryland State Medical Journal 14 61 65 1:STN:280:DyaF2M%2FmtlCltA%3D%3D 14258950
30. K Unnebrink J Windeler 2001 Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases Statistics in Medicine 20 24 3931 3946 1:STN:280:DC%2BD38%2Fls1Sltw%3D%3D 10.1002/sim.1149 11782044 (Pubitemid 34030947)
31. PL Chan NH Holford 2001 Drug treatment effects on disease progression Annual Review of Pharmacology and Toxicology 41 625 59 1:CAS:528: DC%2BD3MXjsVaqt7s%3D 10.1146/annurev.pharmtox.41.1.625 11264471 (Pubitemid 32385901)
32. P Lyden A Shuaib K Ng K Levin RP Atkinson A Rajput L Wechsler T Ashwood L Claesson T Odergren E Salazar-Grueso 2002 Clomethiazole acute stroke study in ischemic stroke (CLASS-I): final results Stroke 33 1 122 128 1:CAS:528:DC%2BD38XhtFSgsr0%3D 10.1161/hs0102.101478 11779900 (Pubitemid 34052197)
33. Beal S, Sheiner LB, Boeckmann A, Bauer RJ, NONMEM User's Guides. (1989-2009), Icon Development Solutions, Ellicott City, MD, USA, 2009.
34. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming Computer Methods and Programs in Biomedicine 75 2 85 94 10.1016/j.cmpb.2003.11.003 15212851 (Pubitemid 38798039)
35. L Lindbom P Pilgren EN Jonsson 2005 PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Computer Methods and Programs in Biomedicine 79 3 241 257 10.1016/j.cmpb.2005. 04.005 16023764 (Pubitemid 41196689)
36. MK Olsen JL Schafer 2001 A two-part random-effects model for semicontinuous longitudinal data Journal of the American Statistical Association 96 454 730 745 10.1198/016214501753168389 (Pubitemid 33283752)
37. JW Mandema DR Stanski 1996 Population pharmacodynamic model for ketorolac analgesia Clinical Pharmacology and Therapeutics 60 6 619 1:CAS:528: DyaK2sXms1eqtg%3D%3D 10.1016/S0009-9236(96)90210-6 8988064 (Pubitemid 27025909)
38. EN Jonsson LB Sheiner 2002 More efficient clinical trials through use of scientific model-based statistical tests Clinical Pharmacology and Therapeutics 72 6 603 10.1067/mcp.2002.129307 12496742 (Pubitemid 36021000)
39. J Xu SL Zeger 2001 Joint analysis of longitudinal data comprising repeated measures and times to events Applied Statistics 50 3 375 387 1:CAS:528:DC%2BD3MXms1Kntbg%3D (Pubitemid 33399970)
40. C Hu ME Sale 2003 A joint model for nonlinear longitudinal data with informative dropout Journal of Pharmacokinetics and Pharmacodynamics 30 1 83 10.1023/A:1023249510224 12800808 (Pubitemid 36571070)
41. RM Altman 2007 Mixed hidden Markov models: an extension of the hidden Markov model to the longitudinal data setting Journal of the American Statistical Association 102 477 201 210 1:CAS:528:DC%2BD2sXisVyqs7k%3D 10.1198/016214506000001086